N-methylaniline

We are N-methylaniline CAS:100-61-8 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:N-methylaniline
CAS.NO:100-61-8
Synonyms:N-methylaniline
N-Phenylmethylamine
N-methyl-aminobenzene
N-Methylbenzenamine
N-methyl-aniline
 
Physical and Chemical Properties:
Density 1.0±0.1 g/cm3
Boiling Point 196.2±0.0 °C at 760 mmHg
Melting Point −57 °C(lit.)
Molecular Formula C7H9N
Molecular Weight 107.153
Flash Point 78.9±0.0 °C
Vapour Pressure 0.4±0.3 mmHg at 25°C
Index of Refraction 1.573
 
Specification:
Appearance:Light yellow to brown liquid
Assay:≥98.0%
 
Packing:200 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Mefenacet(CAS:73250-68-7) Buprofezin(CAS:69327-76-0).

N-methylaniline


Related News: Many domestic raw material pharmaceutical and intermediate manufacturing companies with strong capital and talent reserves and advanced technology and processes have developed in the country, and the competitiveness of market participants has continued to increase.Isotiocianato de 4-metilfenilo CAS:622-59-3 From the perspective of the overall life cycle of generic drugs from R & D to sales, with the expiration of patents, the business model for the production and marketing of generic pharmaceutical raw materials has changed, demand has increased, business potential has been realized quickly, and gross profit margins have shown a downward trend.5-Bromo-2,4-difluorotoluene This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?11,11-dimetil-5,11-dihidroindeno [1,2-b] carbazol CAS:1260228-95-2 This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?The company has now selected a single engineered iPSC clone, and generated and fully-characterized the master engineered iPSC bank for GMP production of FT819.

Related Products
Product Name
Nifalatide View Details
Octyl 4-methoxycinnamate View Details
2-[4,7-bis(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid View Details
3,7,8-trichloro-2-methylquinoline manufacturer 2′-Deoxycytidine-5′-monophosphate disodium salt manufacturer Vapreotide acetate manufacturer leupeptin manufacturer 3-Chloro-4-fluorobenzotrifluoride manufacturer